[Chronic hepatitis C associated with porphyria cutanea tarda]. 1994

K Dohmen, and H Nakamura, and C Morita, and K Arase, and Y Yokogawa, and R Asayama, and H Ishibashi
Department of Internal Medicine, Hamanomachi General Hospital.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D006526 Hepatitis C INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown. Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted,Parenterally-Transmitted Non-A, Non-B Hepatitis,PT-NANBH,Parenterally Transmitted Non A, Non B Hepatitis
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077190 Interferon alpha-2 Alpha interferon encoded by the human IFNA2 gene. Recombinant forms are used in the treatment of CHRONIC HEPATITIS B; CHRONIC HEPATITIS C; KAPOSI SARCOMA; MELANOMA; and HAIRY CELL LEUKEMIA. IFN-alpha 2,IFN-alpha-2,IFNalpha-2b, Recombinant,Interferon alfa-2a,Interferon alfa-2b,Interferon alpha-2b, Recombinant,Interferon alpha-A,Interferon-alpha 2,Intron A (Interferon),LeIF A,Reaferon,Recombinant Interferon alpha-2a,Recombinant Interferon alpha-2b,Ro 22-8181,Roferon-A,Sch-30500,Viferon,IFNalpha 2b, Recombinant,Interferon alfa 2a,Interferon alfa 2b,Interferon alpha 2,Interferon alpha 2b, Recombinant,Interferon alpha A,Interferon alpha-2a, Recombinant,Recombinant IFNalpha-2b,Recombinant Interferon alpha 2a,Recombinant Interferon alpha 2b,Ro 22 8181,Ro 228181,Roferon A,RoferonA,Sch 30500,Sch30500
D016898 Interferon-alpha One of the type I interferons produced by peripheral blood leukocytes or lymphoblastoid cells. In addition to antiviral activity, it activates NATURAL KILLER CELLS and B-LYMPHOCYTES, and down-regulates VASCULAR ENDOTHELIAL GROWTH FACTOR expression through PI-3 KINASE and MAPK KINASES signaling pathways. Interferon Alfa,Interferon, Leukocyte,Interferon, Lymphoblast,alpha-Interferon,IFN-alpha D,IFN-alpha5,Interferon alpha-1,Interferon alpha-17,Interferon alpha-4,Interferon alpha-5,Interferon alpha-7,Interferon alpha-88,Interferon alpha-J,Interferon alpha-T,Interferon alpha4,Interferon alpha5,Interferon, Lymphoblastoid,Interferon, alpha,LeIF I,LeIF J,Leif D,IFN alpha D,IFN alpha5,Interferon alpha,Interferon alpha 1,Interferon alpha 17,Interferon alpha 4,Interferon alpha 5,Interferon alpha 7,Interferon alpha 88,Interferon alpha J,Interferon alpha T,Leukocyte Interferon,Lymphoblast Interferon,Lymphoblastoid Interferon,alpha Interferon
D017119 Porphyria Cutanea Tarda An autosomal dominant or acquired porphyria due to a deficiency of UROPORPHYRINOGEN DECARBOXYLASE in the LIVER. It is characterized by photosensitivity and cutaneous lesions with little or no neurologic symptoms. Type I is the acquired form and is strongly associated with liver diseases and hepatic toxicities caused by alcohol or estrogenic steroids. Type II is the familial form.

Related Publications

K Dohmen, and H Nakamura, and C Morita, and K Arase, and Y Yokogawa, and R Asayama, and H Ishibashi
June 2021, The New England journal of medicine,
K Dohmen, and H Nakamura, and C Morita, and K Arase, and Y Yokogawa, and R Asayama, and H Ishibashi
January 1997, Hepato-gastroenterology,
K Dohmen, and H Nakamura, and C Morita, and K Arase, and Y Yokogawa, and R Asayama, and H Ishibashi
June 1995, Nihon rinsho. Japanese journal of clinical medicine,
K Dohmen, and H Nakamura, and C Morita, and K Arase, and Y Yokogawa, and R Asayama, and H Ishibashi
January 1995, The Medical journal of Australia,
K Dohmen, and H Nakamura, and C Morita, and K Arase, and Y Yokogawa, and R Asayama, and H Ishibashi
June 1996, Cutis,
K Dohmen, and H Nakamura, and C Morita, and K Arase, and Y Yokogawa, and R Asayama, and H Ishibashi
December 1994, Journal of the American Academy of Dermatology,
K Dohmen, and H Nakamura, and C Morita, and K Arase, and Y Yokogawa, and R Asayama, and H Ishibashi
November 2001, Orvosi hetilap,
K Dohmen, and H Nakamura, and C Morita, and K Arase, and Y Yokogawa, and R Asayama, and H Ishibashi
March 2006, Deutsche medizinische Wochenschrift (1946),
K Dohmen, and H Nakamura, and C Morita, and K Arase, and Y Yokogawa, and R Asayama, and H Ishibashi
June 1994, Medicina clinica,
K Dohmen, and H Nakamura, and C Morita, and K Arase, and Y Yokogawa, and R Asayama, and H Ishibashi
May 1998, AIDS patient care and STDs,
Copied contents to your clipboard!